Registry study of genetic changes in melanoma patients in Taiwan
Studies genetic changes in people with melanoma of the extremities.
Plain-language title generated from the registry record
Registry title: The Registry Study of Genetic Alterations of Melanoma in Taiwan
Key facts
- Where
- Chiayi City, Kaohsiung City, Sindian City, Taichung, Tainan, Taipei, and Taoyuan, TaiwanSee the 16 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with melanoma confirmed by tissue testing, from early to advanced disease, who agree to give tumor tissue and have regular follow-up.
- Age
- Older than 18 years
- Sex
- All sexes
- Disease stage
- Melanoma of any stage: stage I/II (early), stage III that can be removed by surgery, or stage III/IV or recurrent melanoma that cannot be removed. Staging follows AJCC 8th edition.
- Biomarker or test result
- Advanced melanoma with an available comprehensive NGS report is placed in cohort 4. Tumor tissue must be available for genetic testing.
Main reasons for not taking part
- Cannot give a complete medical history
- No tumor tissue available for genetic testing (archived tissue more than 5 years old from the screening date)
- Mental state not fit for further treatment or data collection
Read by machine on 9 November 2026.
Where in Taiwan
- Chang-Gung Memorial Hospital - ChiayiChiayi City, TaiwanContact: FENG-CHE KUANTaking people
- Kaohsiung Chang Gung Memorial HospitalKaohsiung City, TaiwanContact: Yen-Hao ChenTaking people
- Kaohsiung Medical UniversityKaohsiung City, TaiwanContact: Hui-Hua HsiaoTaking people
- National Taiwan University Hospital ,NTUH Hsin-Chu BranchSindian City, TaiwanContact: Jih-Hsiang LeeTaking people
- China Medical University HospitalTaichung, TaiwanContact: Chen-Yuan LinTaking people
- Chung Shan Medical University HospitalTaichung, TaiwanContact: Ming-Fang WuTaking people
- Taichung Veterans General HospitalTaichung, TaiwanContact: Young-sen YangTaking people
- National Cheng Kung University HospitalTainan, TaiwanContact: Chia-Jui YenTaking people
- Koo Foundation Sun Yat-Sen Cancer CenterTaipei, TaiwanContact: Hsiao-Hsiang ChengTaking people
- MacKay Memorial HospitalTaipei, TaiwanContact: Yi-Fang ChangTaking people
- National Taiwan University HospitalTaipei, TaiwanContact: Chia-Chi LinTaking people
- Taipei Medical University -Ministry of Health and Welfare Shuang-Ho HospitalTaipei, TaiwanContact: Yao-Yu HsiehTaking people
- Taipei Veterans General HospitalTaipei, TaiwanContact: Chuan-Yen ChuehTaking people
- Wan Fang Hospital, Taipei Medical UniversityTaipei, TaiwanContact: Chia-Lun ChangTaking people
- Chang Gung Memorial Hospital, LinkouTaoyuan, TaiwanContact: Wen-Cheng ChangTaking people
- Taoyuan General Hospital, Ministry of Health and WelfareTaoyuan, TaiwanContact: Yuan-Hao YangTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- National Health Research Institutes, Taiwan
- Trial code
- NCT06952400
- Record updated
- 6 May 2025
- Original description
Cutaneous melanoma is the most aggressive malignancy in skin cancers. Cutaneous melanoma is a rare disease in Taiwan with an incidence rate of around 1/100,000. Acral lentiginous melanoma is the most common subtype and comprises more than half of cutaneous melanoma in Asia including Taiwan but only 1% in Caucasians. In addition, mucosal melanoma accounts for more than 20% of malignancy melanoma in Taiwan but only 1% in Caucasians. Acral and mucosal melanomas have distinct epidemiological, clinical, pathological and genetic features from non-acral melanoma which is commonly seen in Western countries. Comparing with melanoma in Caucasians, Asian melanoma has higher recurrence rate after primary surgery, lower response rate to immunotherapy, and shorter progression-free survival for immunotherapy and targeted therapy leading generally poor survival outcomes regardless stage.Read full original descriptionShow less
T1622 The Registry Study of Genetic Alterations of Melanoma in Taiwan
Cutaneous melanoma is the most aggressive malignancy in skin cancers. Cutaneous melanoma is a rare disease in Taiwan with an incidence rate of around 1/100,000. Acral lentiginous melanoma is the most common subtype and comprises more than half of cutaneous melanoma in Asia including Taiwan but only 1% in Caucasians. In addition, mucosal melanoma accounts for more than 20% of malignancy melanoma in Taiwan but only 1% in Caucasians. Acral and mucosal melanomas have distinct epidemiological, clinical, pathological and genetic features from non-acral melanoma which is commonly seen in Western countries. Comparing with melanoma in Caucasians, Asian melanoma has higher recurrence rate after primary surgery, lower response rate to immunotherapy, and shorter progression-free survival for immunotherapy and targeted therapy leading generally poor survival outcomes regardless stage.
Inclusion: Age > 18 years old; Pathologically confirmed melanoma. (Patients with additional malignancies requiring treatment or follow-up are allowed. Only treatment for melanoma should be recorded); ECOG performance status < 3; Cohort 1(early acral melanoma): melanoma, stage I/II; Cohort 2 (locally advanced acral melanoma): melanoma, stage III, resectable; and Cohort 3 (advanced): unresectable / metastatic melanoma, stage III/IV or recurrent melanoma (unresectable). Staging is based on AJCC Cancer Staging System 8th edition). The patients with advanced melanoma with available comprehensive NGS report are included in cohort 4; Willingness to provide archival or newly obtained tumor tissues for this study proposal; Life expectancy more than 3 months -; Patients fully understand the protocol with the willingness to have regular follow-up.
Exclusion: Inability to cooperate by providing a complete medical history; No available tumor tissues for genetic testing (archived tissue sampling more than 5 years from screening date); Undesirable compliance (Mental status is not fit for further treatment or data collection.).